What Now, What Next?
Appropriate Management of mUC
How I Practice Video #2: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Bonum CE
This program has been supported by independent educational grants from Astellas, Gilead Sciences Inc., Merck Sharp & Dohme LLC, and Seagen.
Program Overview
Locally advanced or metastatic urothelial carcinoma (mUC) is an aggressive form of cancer with a poor prognosis, with a survival of 12–15 months with cisplatin-based combination chemotherapy, but only 3 to 6 months if left untreated. However, up to 50% of patients are ineligible to receive standard platinum-based treatment regimens due to the presence of comorbid conditions, and most who do receive treatment, eventually develop progressive disease. Recent developments have led to the approval of three new classes of agents that have vastly expanded treatment options for patients with mUC. With the expansion of the therapeutic armamentarium, the oncology care team is faced with interpreting a significant amount of new data, evolving guidelines, and nuanced considerations in clinic regarding practical application of these agents.
This series of CME-certified, social media-based activities will provide learners with information regarding new and evolving classes of therapies, updated guidelines in the US and EU, as well as information regarding treatment safety profiles and appropriate management of adverse events.
This video-based activity focuses on US and EU guidelines for managing mUC.
Faculty
Tian Zhang, MD, MHS (program co-chair)
Associate Professor
Director of Clinical Research
Division of Hematology and Oncology Department of Internal Medicine
UT Southwestern Medical Center
Dallas, TX
Andrea Apolo, MD (guest faculty)
Medical Oncologist
Physician-Scientist
Bethesda, MD
Target Audience
This program is intended for medical, surgical, radiation oncologists, urologists, fellows, trainees, oncology advance practice providers, oncology nurses, and oncology pharmacists caring for patients with mUC.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
•DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma
•SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma
Disclosure of Relevant Financial Relationships
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
-
Tian Zhang, MD, MHS (program co-chair)
Consultant/Advisor/Speaker: Aravive, Astra Zeneca, Aveo Therapeutics, Bayer, BMS, Caris, Eisai, Eli Lilly, EMD Serono, Exelixis, Gilead, Janssen, Merck, Pfizer, Sanofi Aventis, SeaGen
Researcher: ALX Oncology, Astellas, Astra Zeneca, Eli Lilly, Janssen, Merck, Novartis, PfizerAndrea Apolo, MD (guest faculty)
Nothing to disclose.
Joint Accreditation Statement
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bonum CE. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit & Fee Information
In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-test, complete the evaluation and application for credit form.
There is no fee to participate in this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimers
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
System Requirements
All Bonum CE digital activities require the following hardware/software to view and participate:
Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)
PowerPoint and/or a PDF viewer may be required on some activities
We recommend a minimum of:
128MB RAM
Processor speed of 500MHz or higher
800x600 color monitor
Video or graphics card
Sound card and speakers
To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.
For additional information about the accreditation of this activity, please visit https://www.partnersed.com
Release date: May 30, 2024
Expiration date: May 30, 2025
Estimated time to complete activity: 30 minutes